CiRC Biosciences

About CiRC Biosciences

CiRC Biosciences is a privately held company specializing in cell therapy, particularly focusing on treatments for severe eye diseases that currently lack effective solutions. Founded in 2019, the company is in the pre-clinical development stage, working on innovative treatments using chemically induced retinal cells. These treatments aim to restore vision for conditions such as Geographic Atrophy Age-Related Macular Degeneration (GA-AMD) and advanced Retinitis Pigmentosa (RP). Unlike traditional stem cell therapies, CiRC's technology bypasses the need for stem cells, which has generated significant interest in the medical community.

CiRC's primary clients are likely to be healthcare providers, research institutions, and potentially pharmaceutical companies interested in cutting-edge cell therapy solutions. The company operates in the biotechnology and healthcare market, focusing on a niche segment of ophthalmology, which deals with eye diseases.

The business model of CiRC revolves around research and development (R&D) of its proprietary cell therapy technologies. By achieving milestones in their pre-clinical and clinical trials, they can attract funding from investors, grants, and partnerships with larger pharmaceutical companies. Additionally, obtaining designations like the Orphan Drug Designation for their RP treatment can provide financial incentives and market exclusivity, further enhancing their revenue potential.

CiRC makes money through a combination of funding rounds, grants, and potential future licensing deals or sales of their developed therapies. As they progress through clinical trials and move towards market approval, the company can also explore partnerships or acquisitions by larger biotech firms, providing additional revenue streams.